Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A6 | P11509 | 2/20 | 0.33 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.31 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.31 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.31 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.31 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5048686 | 0.79 | CYP2A6 (0.33) | CYP2A6DYRK1AMRGPRX4SLC6A2SLC6A4 | |
| SCHEMBL13742552 | 0.70 | DYRK1A (0.48) | CYP2A6DYRK1AMRGPRX4SLC6A2SLC6A4 | |
| SCHEMBL164774 | 0.69 | CYP2A6 (0.50) | CYP2A6DYRK1A | |
| SCHEMBL19914470 | 0.67 | CYP2A6 (0.36) | CYP2A6DYRK1AMRGPRX4SLC6A2SLC6A4 | |
| SCHEMBL18725843 | 0.67 | CYP2A6 (0.36) | CYP2A6DYRK1AMRGPRX4SLC6A2SLC6A4 | |
| SCHEMBL2009270 | 0.67 | CYP2A6 (0.36) | CYP2A6DYRK1AMRGPRX4SLC6A2SLC6A4 | |
| SCHEMBL276241 | 0.67 | CYP2A6 (0.41) | CYP2A6DYRK1AMRGPRX4SLC6A2SLC6A4 | |
| SCHEMBL422225 | 0.67 | CYP2A6 (0.48) | CYP2A6SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL153668 | 0.67 | CYP2A6 (0.41) | CYP2A6DYRK1AMRGPRX4SLC6A2SLC6A4 | |
| SCHEMBL405354 | 0.67 | CYP2A6 (0.41) | CYP2A6DYRK1AMRGPRX4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11787796-B2 | Plasma Kallikrein inhibitors and uses thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-10-17 | — | — | US | disclosed |
| US-20180030026-A1 | INHIBITORS OF THE KYNURENINE PATHWAY | CURADEV PHARMA PVT LTD | 2018-02-01 | — | — | US | disclosed |
| US-9815811-B2 | Inhibitors of the kynurenine pathway | CURADEV PHARMA, PVT. LTD. (IN) | 2017-11-14 | — | — | US | disclosed |
| US-20160046596-A1 | INHIBITORS OF THE KYNURENINE PATHWAY | CURADEV PHARMA PRIVATE LTD. (IN) | 2016-02-18 | — | — | US | disclosed |
| US-8580780-B2 | 6 substituted 2, 3,4,5 tetrahydro-1H-benzo[d]azepines as 5-HT2C receptor agonist | ELI LILLY AND COMPANY (US) | 2013-11-12 | — | — | US | disclosed |
| US-20120028961-A1 | 6 Substituted 2, 3,4,5 Tetrahydro-1H-Benzo[d]Azepines as 5-HT2c Receptor Agonist | ELI LILLY AND COMPANY (US) | 2012-02-02 | — | — | US | disclosed |
| US-8022062-B2 | 6-substituted 2,3,4,5-tetrahydro-1H-benzo[d]azepines as 5-HT2C receptor agonists | ELI LILLY AND COMPANY (US) | 2011-09-20 | — | — | US | disclosed |
| US-20110086877-A1 | Small Molecule Inhibitors of Botulinum Neurotoxins | BAVARI SINA | 2011-04-14 | — | — | US | disclosed |
| US-7825154-B2 | Small molecule inhibitors of botulinum neurotoxins | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE ARMY (US) | 2010-11-02 | — | — | US | disclosed |
| US-20090099155-A1 | 6-SUBSTITUTED 2,3,4,5-TETRAHYDRO-1H-BENZO[D]AZEPINES AS 5-HT2C RECEPTOR AGONISTS | ARRAY BIOPHARMA, INC. | 2009-04-16 | — | — | US | disclosed |
| US-20070112049-A1 | nonpeptidic inhibitors of Botulinum neurotoxin A metalloprotease activity, such as 2-[4-(4-carbamimidoylphenoxy)phenyl]-1H-indole-5-carboximidamide, used for treating, inhibiting or preventing intoxication caused by bacteria | ARMY, UNITED STATES | 2007-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090099155-A1 | 6-SUBSTITUTED 2,3,4,5-TETRAHYDRO-1H-BENZO[D]AZEPINES AS 5-HT2C RECEPTOR AGONISTS | HTR2C, HTR5A, HTR4 | CYP2A6 799/4885DYRK1A 1266/4885MRGPRX4 413/4885 |
| US-11787796-B2 | Plasma Kallikrein inhibitors and uses thereof | KLKB1, KLK1, KLK5 | CYP2A6 2270/4885DYRK1A 2801/4885MRGPRX4 906/4885 |
| US-20180030026-A1 | INHIBITORS OF THE KYNURENINE PATHWAY | IDO1, IDO2, KYNU | CYP2A6 132/4885DYRK1A 641/4885MRGPRX4 873/4885 |
| US-20070112049-A1 | nonpeptidic inhibitors of Botulinum neurotoxin A metalloprotease activity, such as 2-[4-(4-carbamimidoylphenoxy)phenyl]-1H-indole-5-carboximidamide, used for treating, inhibiting or preventing intoxication caused by bacteria | ACHE, CTRL, MMP2 | CYP2A6 2184/4885DYRK1A 3649/4885MRGPRX4 1201/4885 |
| US-20160046596-A1 | INHIBITORS OF THE KYNURENINE PATHWAY | IDO1, KYNU, IDO2 | CYP2A6 125/4885DYRK1A 543/4885MRGPRX4 1088/4885 |
| US-20120028961-A1 | 6 Substituted 2, 3,4,5 Tetrahydro-1H-Benzo[d]Azepines as 5-HT2c Receptor Agonist | HTR2C, HTR4, HTR1A | CYP2A6 438/4885DYRK1A 1025/4885MRGPRX4 230/4885 |
| US-20110086877-A1 | Small Molecule Inhibitors of Botulinum Neurotoxins | ACHE, MMP2, TIMP3 | CYP2A6 2198/4885DYRK1A 3686/4885MRGPRX4 1319/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.